CPH · NOVO-B.CO
Novo Nordisk A/S
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
Loading market information…
CPH · HLUN-B.CO · DKK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 03:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · DKK. Historical prices are not a forecast.
H. Lundbeck A/S’s quoted price sits in the upper half of its reported 52-week range, 0.64% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
H. Lundbeck A/S’s forward annual dividend is DKK 1.15 per share, paid annual. The forward yield is 2.11% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
H. Lundbeck A/S’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of DKK 1.11. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow H. Lundbeck A/S’s reporting calendar.
THE COMPANY BEHIND THE TICKER
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomatic neurogenic orthostatic hypotension; Onfi for epilepsy; Sabril for refractory complex partial seizures and infantile spasms; Ebixa for dementia, Azilect for Parkinson’s disease; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol for psychosis. In addition, the company develops Eptinezumab for migraine prevention; Eptinezumab, which is in phase 3 clinical trial for cluster headache; Lu AG09222, which is in phase 2 clinical trial for migraine prevention; Lu AG13909 that is in phase 1 clinical trial for neurohormonal dysfunctions; Brexpiprazole for post-traumatic stress disorder; Lu AF28996, which is in phase 1 clinical trial for Parkinson’s disease; MAGLi program that is in phase 1 clinical trial for neurology; Bexicaserin, which is in phase 3 clinical trial for developmental and epileptic encephalopathies; Amlenetug that is in phase 3 clinical trial for synucleinopathies; and Lu AG22515, which is in clinical phase 1 clinical trial for neurology. Lundbeck A/S has a strategic research collaboration with Contera Pharma to develop oligonucleotide-based medicines for patients living with serious neurological conditions. The company was founded in 1915 and is headquartered in Valby, Denmark.
Latest available per-share figures in DKK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:44 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | May 14, 2025 | DKK 1.16+29.61% vs estimate | DKK 6.24B+8.54% vs estimate |
|---|
| Q4 2024 | Feb 5, 2025 | DKK 0.60+41.88% vs estimate | DKK 5.54B-2.63% vs estimate |
|---|
| Q3 2024 | Nov 13, 2024 | DKK 0.78-39.53% vs estimate | DKK 5.72B+4.01% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
DKK 260.35+DKK 5.35 (+2.1%)
Novo Nordisk A/S’s quoted price sits in the lower half of its reported 52-week range, 36.49% below the high.
DKK 3,788.00-DKK 80.00 (-2.07%)
Genmab A/S’s quoted price sits in the upper half of its reported 52-week range, 3.49% below the high.
$253.00+$3.45 (+1.38%)
Ascendis Pharma A/S’s quoted price sits in the upper half of its reported 52-week range, 10.33% below the high.
DKK 477.00-DKK 1.50 (-0.31%)
Coloplast A/S’s quoted price sits in the lower half of its reported 52-week range, 24.45% below the high.
DKK 366.00+DKK 3.20 (+0.88%)
Demant A/S’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
DKK 246.60+DKK 3.00 (+1.23%)
ALK-Abelló A/S’s quoted price sits in the upper half of its reported 52-week range, 9.14% below the high.
DKK 247.80-DKK 7.80 (-3.05%)
Bavarian Nordic A/S’s quoted price sits in the upper half of its reported 52-week range, 3.58% below the high.
DKK 78.60-DKK 1.40 (-1.75%)
Ambu A/S’s quoted price sits in the lower half of its reported 52-week range, 24.86% below the high.
